{
    "clinical_study": {
        "@rank": "106105", 
        "brief_summary": {
            "textblock": "To evaluate the benefit of adding 1592U89 to current antiretroviral therapies for AIDS\n      dementia complex and to assess the safety and tolerance of the treatment regimens."
        }, 
        "brief_title": "A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex", 
        "condition": [
            "AIDS Dementia Complex", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "AIDS Dementia Complex", 
                "Dementia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients must be on stable antiretroviral treatment for at least 6 weeks prior to study\n      entry and will then be stratified depending on whether their regimen contains zidovudine\n      (ZDV).  Each stratum will be randomized separately to receive 1592U89 or placebo for 12\n      weeks. For the subsequent 40 weeks, open-label 1592U89 will be offered."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Documented HIV infection.\n\n          -  Evidence of HIV - associated dementia.\n\n          -  Been on stable antiretroviral treatment for a minimum of 6 weeks prior to study\n             entry.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with any of the following symptoms or conditions are excluded:\n\n          -  Debilitated as a result of their HIV disease, associated illness or therapies who the\n             investigator determines will not be able to complete the 12 week randomized dosing\n             period.\n\n          -  Memorial Sloan-Kettering (MSK) score of >= 3 for dementia.\n\n          -  Confounding neurological diseases which may interfere with interpretation of\n             neurological and neurophysical assessments.\n\n          -  Malabsorption syndrome or other gastrointestinal dysfunction which renders them\n             unable to take oral medication.\n\n          -  Chronic diseases such as diabetes, congestive heart failure, cardiomyopathy, other\n             cardiac dysfunctions, etc., which in the investigator's opinion would compromise the\n             safety of the patient.\n\n          -  Symptomatic AIDS-defining opportunistic infection not responsive to therapy.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Treatment with cytotoxic chemotherapeutic agents within the first 12 weeks of the\n             study.\n\n          -  Treatment with nerve growth factor within the first 12 weeks of study.\n\n          -  The use of narcotic analgesics, sedatives, benzodiazepines, antidepressants,\n             anti-psychotic agents and other psychoactive drugs which would interfere with the\n             assessment of the neurological and neurophysical status of the patient.\n\n          -  Use of stavudine (d4T) during the first 12 weeks of the study.\n\n          -  Immunomodulating agents (except GM/G-CSF or epoietin).\n\n          -  Psychoactive drugs (at the investigator's discretion).\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Treatment with radiation therapy within the first 12 weeks of the study.\n\n        NOTE:\n\n          -  With the exception of local treatment for Kaposi's sarcoma.\n\n        Patients with any of the following prior conditions are excluded:\n\n          -  Previous neurological disease unrelated to HIV infection.\n\n          -  History of clinically apparent hepatitis within the last 6 months.\n\n          -  History of clinically apparent pancreatitis in the last 6 months.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Treatment with cytotoxic chemotherapeutic agents within 1 month of entry.\n\n          -  Participation in investigational antiretroviral trials within the past 3 months.\n\n          -  HIV vaccine within the past 3 months.\n\n          -  Treatment with immunomodulating agents such as systemic corticosteroids,\n             interleukins, thalidomide, anticytokine agents, anti-oxidants or interferons within 1\n             month of study entry.\n\n          -  Nerve growth factor.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Treatment with radiation therapy within 1 month of entry.\n\n        NOTE:\n\n          -  With the exception of local treatment for Kaposi's sarcoma.\n\n        Risk Behavior:\n\n        Excluded:\n\n        Current alcohol or illicit drug use which may interfere with the patient's ability to\n        comply with the study protocol.\n\n        Required:\n\n          -  Stable antiretroviral treatment that has been ongoing for a minimum of 6 weeks prior\n             to study entry, may or may not include ZDV.\n\n        Required:\n\n          -  Stable antiretroviral treatment for a minimum of 6 weeks prior to study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002163", 
            "org_study_id": "238B", 
            "secondary_id": "CNAB 3001"
        }, 
        "intervention": {
            "intervention_name": "Abacavir sulfate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Abacavir"
        }, 
        "keyword": [
            "Acquired Immunodeficiency Syndrome", 
            "AIDS Dementia Complex", 
            "Antiviral Agents", 
            "abacavir"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92103"
                    }, 
                    "name": "HIV Neurobehavioral Research Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94110"
                    }, 
                    "name": "San Francisco Gen Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Johns Hopkins Univ School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington Univ Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia Univ / Sergievsky Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10029"
                    }, 
                    "name": "Mount Sinai Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "Univ of North Carolina School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winnipeg", 
                        "country": "Canada", 
                        "state": "Manitoba"
                    }, 
                    "name": "Univ of Manitoba / Faculty of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "Wellesley Hosp"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "official_title": "A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "reference": {
            "PMID": "11371689", 
            "citation": "Lanier ER, Sturge G, McClernon D, Brown S, Halman M, Sacktor N, McArthur J, Atkinson JH, Clifford D, Price RW, Simpson D, Torres G, Catalan J, Marder K, Power C, Hall C, Romero C, Brew B. HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir. AIDS. 2001 Apr 13;15(6):747-51."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002163"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glaxo Wellcome", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 1998"
    }, 
    "geocoordinates": {
        "Columbia Univ / Sergievsky Ctr": "40.714 -74.006", 
        "HIV Neurobehavioral Research Ctr": "32.715 -117.157", 
        "Johns Hopkins Univ School of Medicine": "39.29 -76.612", 
        "Mount Sinai Med Ctr": "40.714 -74.006", 
        "San Francisco Gen Hosp": "37.775 -122.419", 
        "Univ of Manitoba / Faculty of Medicine": "49.9 -97.137", 
        "Univ of North Carolina School of Medicine": "35.913 -79.056", 
        "Washington Univ Med Ctr": "38.627 -90.199", 
        "Wellesley Hosp": "43.653 -79.383"
    }
}